Can One Health Strategies Be More Effectively Implemented Through Prior Identification Of Public Values?
Funder
National Health and Medical Research Council
Funding Amount
$585,331.00
Summary
Emerging infectious diseases (EIDs) are a significant risk to our region. One Health approaches to EIDs emphasize connections between human,animal and ecological health, enhancing capacity for disease prediction and intervention. This project will examine existing EID legislation,identify social and ethical barriers to effective EID risk governance and create a comprehensive statement of values to ensure the acceptability of One Health approaches to EID control to the Australian community.
Alcohol And Other Drug Treatment Funding, Purchasing And Workforce: Empirical Analyses To Inform Policy
Funder
National Health and Medical Research Council
Funding Amount
$473,865.00
Summary
Alcohol and drug treatment works: it improves health and reduces the social impact of alcohol and drug use. The treatment itself is not, however, the only variable that impacts on whether health outcomes are improved. The way in which governments fund, purchase and structure the treatment service system is also important. This study will empirically test the relationship between treatment outcome and the structures that governments put in place, providing new evidence to inform decision-making.
Rates, Patterns And Determinants Of Alcohol’s Harm To Others: A Cross-national Comparative Study
Funder
National Health and Medical Research Council
Funding Amount
$305,856.00
Summary
Alcohol causes harms to drinkers, and others around them, including spouses, children, family, friends, workmates and strangers. Australian and New Zealand work on alcohol’s harm to others is being replicated by the WHO in 7 countries (Chile, Nigeria, Sri Lanka, India, Thailand, Laos and Vietnam). We aim to analyse datasets from nine countries and compare the magnitude and patterning of problems across and within cultures – identifying opportunities for reducing harm from others’ drinking.
Targeting Drug-Resistance In Paediatric Acute Lymphoblastic Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$649,048.00
Summary
Leukaemia is the most common type of cancer in children but resistance to therapy continues to be a significant problem. This project will investigate the biology of drug-resistance and relapse using a mouse model that replicates the human disease. We hope to identify novel therapeutic targets that can be used in combination with existing therapies to improve outcomes in this disease, particularly for patients that develop drug-resistance such as those at the time of relapse.
An International Clinical Trial To Evaluate New Therapies To Improve Survival Of Children With Relapsed Acute Lymphoblastic Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$1,567,500.00
Summary
Children who relapse with childhood leukaemia have only a 50% chance of being alive after 5 years. We will participate in a new international trial involving most European and all Australian and New Zealand childhood oncology centres, to test the effectiveness of promising new treatments and to perform biological studies which should enable doctors in future to pick the best treatment for each of these patients.